Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line

Efficacy and Safety of DWP450 Compared With Botox in Patients With Moderate to Severe Glabellar Line: Active Controlled, Double-blind, Randomized, Multi-center, Phase I/III Clinical Trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01629875

Enrollment

268

Registered

2012-06-28

Start date

2012-03-31

Completion date

2012-11-30

Last updated

2012-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to Severe Glabellar Line

Brief summary

The purpose of this study was to observe Efficacy and safety of DWP450 compared with Botox in moderate to severe glabellar line patients.

Interventions

DRUGGeneric equivalent of Clostridium Botulinum A Toxin

DRUGBotox (Clostridium Botulinum A Toxin)

Study design

Allocation

RANDOMIZED

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 65 Years

Healthy volunteers

Design outcomes

Primary

Measure	Time frame	Description
At 4 weeks, Glabellar line improvement rate at maximum frown confirmed with investigator's live severity assessment	At 4 weeks	At 4 weeks, Glabellar line improvement rate at maximum frown confirmed with investigator's live severity assessment

Secondary

Measure	Time frame	Description
At 8, 12, 16 weeks, Glabellar line improvement rate at maximum frown confirmed with investigator's live severity assessment	At 8, 12, 16 weeks	At 8, 12, 16 weeks, Glabellar line improvement rate at maximum frown confirmed with investigator's live severity assessment

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026